A meta-analysis has shown that even small increases in a mother's BMI can increase the risk of fetal death, stillbirth, and neonatal, perinatal, and infant death.
Even modest increases in maternal body mass index (BMI) are associated with increased risk of fetal death, stillbirth, and neonatal, perinatal, and infant death, according to a study that recently appeared in The Journal of the American Medical Association.
This was the first meta-analysis to comprehensively summarize results for the relationship between maternal BMI and fetal, perinatal, neonatal, and infant death as well, according to the researchers. They noted that their findings are supported by 2 studies of interpregnancy weight change that reported increased risk of stillbirth in the second pregnancy among women who gained weight between their first and second pregnancies.
The researchers conducted a systematic review and meta-analysis of cohort studies of maternal BMI and risk of fetal death, stillbirth, and infant death by searching the PubMed and Embase databases from inception to January 23, 2014.
For women with BMIs of 20, 25, and 30, absolute risks per 10,000 pregnancies for fetal death were 76, 82, and 102; for stillbirth, 40, 48, and 59; for perinatal death, 66, 73, and 86; for neonatal death, 20, 21, and 24; and for infant death, 33, 37, and 43, respectively.
“Weight management guidelines for women who plan pregnancies should take these findings into consideration to reduce the burden of fetal death, stillbirth, and infant death,” the researchers concluded.
Aune D, et al. Maternal body mass index and the risk of fetal death, stillbirth and infant death: a systematic review and meta-analysis. JAMA. 2014;311(15):1536–1546.
Impact of antiepileptic medications and sex hormones on maternal and child outcomes in epilepsy
May 16th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More
Understanding pediatric STIs: Trends, management, and more
May 10th 2024Dive into the rising prevalence of sexually transmitted infections among adolescents and young adults, exploring educational gaps, vaccination rates, and the imperative need for open conversations between patients and health care providers to combat stigma and enhance preventive care.
Read More